George Rodrigues

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5829163/george-rodrigues-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77 papers	1,967 citations	22 h-index	43 g-index
81 ext. papers	2,427 ext. citations	2.1 avg, IF	4.27 L-index

#	Paper	IF	Citations
77	Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data.. *Oncologist*, **2022**,	5.7	1
76	Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.. *Journal of Urology*, **2022**, 101097JU0000000000002759	2.5	1
75	Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.. *Journal of Urology*, **2022**, 101097JU0000000000002758	2.5	3
74	Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.. *Journal of Urology*, **2022**, 101097JU0000000000002757	2.5	6
73	Uptake of immunotherapy in patients with advanced cancer: A population-based study using health administrative data from Ontario, Canada.. *Journal of Clinical Oncology*, **2021**, 39, 6529-6529	2.2	
72	Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.. *Journal of Clinical Oncology*, **2021**, 39, e17052-e17052	2.2	
71	Characterizing Surgical and Radiotherapy Outcomes in Non-metastatic High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. *Cureus*, **2021**, 13, e17400	1.2	
70	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 943-947	4	20
69	Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: An ASTRO Consensus Paper. *Practical Radiation Oncology*, **2019**, 9, 65-72	2.8	26
68	Radical radiotherapy for locally advanced non-small cell lung cancer-what's up with arm positioning?. *Journal of Thoracic Disease*, **2019**, 11, 2099-2104	2.6	4
67	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. *Cureus*, **2019**, 11, e6394	1.2	2
66	Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. *Practical Radiation Oncology*, **2018**, 8, 245-250	2.8	37
65	The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography. *Journal of Medical Imaging and Radiation Sciences*, **2018**, 49, 76-83	1.4	2
64	Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. *Practical Radiation Oncology*, **2017**, 7, 295-301	2.8	234
63	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. *Canadian Urological Association Journal*, **2017**, 11, 94-100	1.2	
62	Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. *Journal of Medical Imaging*, **2016**, 3, 046002	2.6	1
61	A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis. *Radiotherapy and Oncology*, **2016**, 118, 478-84	5.3	14

60	Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 1121-8	4	95
59	Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. *Clinical Lung Cancer*, **2016**, 17, e141-e149	4.9	35
58	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 612-20	4	32
57	Rebuttal from Prof. Rodrigues. *Translational Lung Cancer Research*, **2016**, 5, 201	4.4	
56	Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer. *Translational Lung Cancer Research*, **2016**, 5, 195-7	4.4	1
55	Optimal sequencing of adjuvant chemotherapy and radiation therapy in resected non-small cell lung cancer with pathological N2 disease. *Journal of Thoracic Disease*, **2016**, 8, E463-5	2.6	1
54	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases. *Journal of Neuro-Oncology*, **2016**, 128, 431-6	4.8	1
53	In Reply to Cobben and Jager. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 700-1	4	2
52	Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. *Practical Radiation Oncology*, **2015**, 5, 141-148	2.8	60
51	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non-Small-Cell Lung Cancer: Is There an Impact on Radiation Pneumonitis Rates?. *Journal of Clinical Oncology*, **2015**, 33, 2927	2.2	3
50	Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 133-9	4	13
49	Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. *Practical Radiation Oncology*, **2015**, 5, 149-155	2.8	29
48	Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 505-16	4	42
47	Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. *Cureus*, **2015**, 7, e276	1.2	6
46	Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature. *Cureus*, **2015**, 7, e238	1.2	6
45	Management of high-grade gliomas in the elderly. *Seminars in Radiation Oncology*, **2014**, 24, 279-88	5.5	14
44	Comparative analysis of image guidance in two institutions for prostate cancer patients. *Reports of Practical Oncology and Radiotherapy*, **2014**, 19, 206-13	1.5	5
43	The prostate cancer risk stratification project: database construction and risk stratification outcome analysis. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 60-9	7.3	11

42	Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods. *Medical Physics*, **2014**, 41, 113503	4.4	10
41	A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. *Radiotherapy and Oncology*, **2014**, 111, 52-8	5.3	27
40	Systematic review of fractionated brain metastases radiotherapy. *Journal of Radiation Oncology*, **2014**, 3, 29-41	0.7	9
39	Systematic review of brain metastases prognostic indices. *Practical Radiation Oncology*, **2013**, 3, 101-6	2.8	13
38	Propensity-score matched pair comparison of whole brain with simultaneous in-field boost radiotherapy and stereotactic radiosurgery. *Radiotherapy and Oncology*, **2013**, 106, 206-9	5.3	14
37	Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 690-6	4	120
36	The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. *Radiotherapy and Oncology*, **2013**, 106, 370-4	5.3	38
35	Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 444-50	4	384
34	The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. *Radiotherapy and Oncology*, **2013**, 109, 204-10	5.3	29
33	Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. *Oncologist*, **2013**, 18, 330-5	5.7	13
32	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review. *Canadian Urological Association Journal*, **2013**, 7, 463-70	1.2	13
31	Palliative Radiotherapy in Advanced Lung Cancer **2013**, 163-176		
30	Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. *Canadian Urological Association Journal*, **2013**, 7, E411-6	1.2	10
29	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review. *Canadian Urological Association Journal*, **2013**, 7, E783-7	1.2	3
28	In regard to Vargo et al: "Early Clinical Outcomes for 3 Radiation Techniques for Brain Metastases: Focal Versus Whole-Brain". *Practical Radiation Oncology*, **2012**, 2, 155	2.8	
27	A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. *Radiotherapy and Oncology*, **2012**, 102, 180-6	5.3	31
26	Categorizing segmentation quality using a quantitative quality assurance algorithm. *Journal of Medical Imaging and Radiation Oncology*, **2012**, 56, 668-78	1.7	4
25	Age and comorbidity considerations related to radiotherapy and chemotherapy administration. *Seminars in Radiation Oncology*, **2012**, 22, 277-83	5.5	21

24	Hyperpolarized (3)He magnetic resonance imaging: comparison with four-dimensional x-ray computed tomography imaging in lung cancer. *Academic Radiology*, **2012**, 19, 1546-53	4.3	60
23	A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. *Radiation Oncology*, **2012**, 7, 42	4.2	16
22	Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. *Clinical Lung Cancer*, **2012**, 13, 1-5	4.9	27
21	International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. *Clinical Lung Cancer*, **2012**, 13, 225-35	4.9	19
20	Pre-treatment risk stratification of prostate cancer patients: A critical review. *Canadian Urological Association Journal*, **2012**, 6, 121-7	1.2	85
19	Future directions in palliative thoracic radiotherapy. *Current Opinion in Supportive and Palliative Care*, **2012**, 6, 91-6	2.6	5
18	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2012**, 19, 6135-41	0.8	
17	Is intensity-modulated radiotherapy for prostate cancer ready for prime-time?. *Canadian Journal of Urology*, **2012**, 19, 6381-2	0.8	1
16	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2012**, 19, 6489-93	0.8	
15	An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: A single institution experience. *Practical Radiation Oncology*, **2011**, 1, 173-81	2.8	5
14	Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. *Practical Radiation Oncology*, **2011**, 1, 60-71	2.8	129
13	Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 445-52	4	10
12	Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1128-33	4	39
11	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2011**, 18, 5574-80	0.8	1
10	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2011**, 18, 5751-6	0.8	1
9	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2011**, 18, 5928-32	0.8	1
8	Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era. *Radiotherapy and Oncology*, **2010**, 95, 166-71	5.3	80
7	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2010**, 17, 5494-9	0.8	

6	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2009**, 16, 4524-30	0.8	
5	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2009**, 16, 4795-800	0.8	
4	Novel application of helical tomotherapy in whole skull palliative radiotherapy. *Medical Dosimetry*, **2008**, 33, 282-5	1.3	7
3	Systematic review of baseline low-dose CT lung cancer screening. *Lung Cancer*, **2007**, 58, 161-70	5.9	29
2	Psychometric properties of a prostate cancer radiation late toxicity questionnaire. *Health and Quality of Life Outcomes*, **2007**, 5, 29	3	6
1	Open clinical uro-oncology trials in Canada. *Canadian Journal of Urology*, **2007**, 14, 3779-86	0.8	